Although the CR rate has dropped, one has to remember that there are now more than twice the patients, so it remains to be seen if the CR rate goes back up as the new patients go through the protocol. What is the most important IMO, is that no one who has received the treatment has progressed to date.
The data is very good and compelling. Whether the market sees through the headline and thinks the same in the short-term is another matter. If it dips and you don't have any, I'd buy a starter and build a position.
GLTA,
Murocman
News 
Market Data 
Discover 
